Journal of neuro-oncology · 2026
Dual AI models for gamma knife radiosurgery in craniopharyngioma: prescription dose modeling and outcome risk prediction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reyes Jheremy S, Bouras Alexandros, Hadjipanayis Constantinos G, Lunsford L Dade, Niranjan Ajay
Аннотация
BACKGROUND: Gamma Knife radiosurgery (GKRS) is an established adjunct for residual or recurrent craniopharyngioma, yet prescription dose selection remains experience-driven and long-term failure risk is difficult to individualize. Machine learning may support more consistent planning and risk-informed follow-up.
OBJECTIVE: To develop and internally validate two complementary AI models for craniopharyngioma GKRS: (1) prescription dose prediction and (2) treated-lesion progression risk prediction.
METHODS: In this retrospective single-center cohort, we trained a random forest regressor to predict delivered single-fraction margin dose (Gy) from baseline clinical and tumor features and a random forest classifier to estimate the probability of treated-lesion progression using baseline features and delivered dose. Internal validation used cross-validation with discrimination and calibration metrics.
RESULTS: Seventy-two treated tumors were analyzed. Prescription dose prediction showed clinically tight error, with MAE 1.30 Gy and RMSE 1.65 Gy (R² 0.21), indicating the model approximated physician dosing patterns within ~1-2 Gy for most cases. For outcome modeling, risk prediction achieved ROC-AUC 0.75 and PR-AUC 0.582, with reasonable calibration (Brier score 0.112; recalibration slope 0.86, intercept 0.096). Together, the two models enabled simultaneous estimation of an expected prescription dose and an individualized probability of long-term treated-lesion failure, supporting risk stratification beyond dose alone.
CONCLUSIONS: A dual-model AI framework for craniopharyngioma GKRS is feasible and provides both dose estimates and individualized long-horizon failure risk predictions, with potential to standardize prescriptions and tailor surveillance intensity.
CLINICAL TRIAL NUMBER: Not applicable.
OBJECTIVE: To develop and internally validate two complementary AI models for craniopharyngioma GKRS: (1) prescription dose prediction and (2) treated-lesion progression risk prediction.
METHODS: In this retrospective single-center cohort, we trained a random forest regressor to predict delivered single-fraction margin dose (Gy) from baseline clinical and tumor features and a random forest classifier to estimate the probability of treated-lesion progression using baseline features and delivered dose. Internal validation used cross-validation with discrimination and calibration metrics.
RESULTS: Seventy-two treated tumors were analyzed. Prescription dose prediction showed clinically tight error, with MAE 1.30 Gy and RMSE 1.65 Gy (R² 0.21), indicating the model approximated physician dosing patterns within ~1-2 Gy for most cases. For outcome modeling, risk prediction achieved ROC-AUC 0.75 and PR-AUC 0.582, with reasonable calibration (Brier score 0.112; recalibration slope 0.86, intercept 0.096). Together, the two models enabled simultaneous estimation of an expected prescription dose and an individualized probability of long-term treated-lesion failure, supporting risk stratification beyond dose alone.
CONCLUSIONS: A dual-model AI framework for craniopharyngioma GKRS is feasible and provides both dose estimates and individualized long-horizon failure risk predictions, with potential to standardize prescriptions and tailor surveillance intensity.
CLINICAL TRIAL NUMBER: Not applicable.